Status:
UNKNOWN
Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis
Lead Sponsor:
Blood Transfusion Centre of Slovenia
Collaborating Sponsors:
University Medical Centre Ljubljana
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
1-16 years
Brief Summary
The purpose of this study is to analyze the frequency of the formation of antibodies against three different anti-TNF biologic agents used for the therapy of juvenile idiopathic arthritis.
Detailed Description
Juvenile idiopathic arthritis (JIA) is the umbrella term for a heterogeneous group of inflammatory arthropathies that can affect children and young adults and is the most common rheumatic disease of t...
Eligibility Criteria
Inclusion
- Clinical diagnosis of juvenile idiopathic arthritis
- Must be treated either with infliximab, adalimumab or etanercept
Exclusion
- Contraindications to anti-TNF therapy
- Concurrent treatment with any biologic agent other than infliximab, etanercept, or adalimumab
- Previous treatment with rituximab
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01436019
Start Date
October 1 2011
End Date
December 1 2012
Last Update
September 19 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Centre
Ljubljana, Slovenia